Maassen M M, Pfister M, Plontke S, Koitschev A, Vögler A, Löwenheim H
Universitätsklinik für Hals-Nasen-Ohren-Heilkunde Tübingen.
HNO. 2002 Dec;50(12):1062-7. doi: 10.1007/s00106-002-0653-5.
For the treatment of idiopathic sudden sensorineural hearing loss (ISSNHL), a variety of studies about intravenous drug administration with the beginning of treatment in the early period of less then one week after the onset of hearing loss have been performed. In contrast, very little information is available about the efficacy of intravenous drug therapy for ISSNHL with the beginning of treatment later than four weeks after the onset of hearing loss. In a retrospective chart review we studied the treatment results of 57 patients with ISSNHL with beginning of treatment later than four weeks after the onset of hearing loss with no spontaneous recovery of hearing. Patients received a treatment with intravenous administration of Dextran (concentration 40 g/l with NaCl 0.9%) and Procain-HCl (a derivative of the local anaesthetic lidocaine,400-800 mg in a 500 ml rheologic infusion of Dextran 40). 25% of the patients showed a significant improvement of 10 dB or more in hearing threshold at 1000 Hz measured in bone-conducted pure tone audiometry. In a subjective evaluation 53% of the patients noticed a subjective improvement of their individual hearing thresholds.
对于特发性突发性感音神经性听力损失（ISSNHL）的治疗，已经开展了多项关于在听力损失发作后一周内尽早开始静脉给药治疗的研究。相比之下，关于在听力损失发作四周后开始治疗的ISSNHL静脉药物治疗效果的信息却非常少。在一项回顾性病历审查中，我们研究了57例听力损失发作四周后开始治疗且听力未自发恢复的ISSNHL患者的治疗结果。患者接受了静脉注射右旋糖酐（浓度为40 g/l，与0.9%的氯化钠混合）和盐酸普鲁卡因（局部麻醉剂利多卡因的衍生物，在500 ml 40右旋糖酐流变学输注液中含400 - 800 mg）的治疗。25%的患者在骨导纯音听力测定中，1000 Hz处的听力阈值显著提高了10 dB或更多。在主观评估中，53%的患者注意到其个人听力阈值有主观改善。
